# Arcturus Therapeutics Holdings Inc. (ARCT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $189M  
**Price:** $6.91 (+0.29%)

> Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines. It leverages proprietary LUNAR lipid-mediated delivery and STARR self-amplifying mRNA platforms to advance its pipeline. Key internal programs include ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032, an inhaled mRNA therapy for cystic fibrosis, both in Phase 2 clinical studies targeting severe patient populations. In vaccines, it partners with CSL Seqirus on mRNA candidates for COVID-19, influenza, and other infectious diseases, with KOSTAIVE approved in Japan, the EU, and the UK, generating initial commercial sales through collaborators like Meiji and CSL Seqirus. The company operates in a single business segment encompassing discovery, development, and commercialization of mRNA medicines. Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a significant role in the biotech sector by pioneering mRNA technologies for rare diseases and partnered vaccine franchises.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $82M | — | -$76M | -$66M | — |
| 2024 | $152M | — | -$96M | -$81M | — |
| 2023 | $167M | — | -$78M | -$30M | — |
| 2022 | $206M | — | $12M | $9M | — |
| 2021 | $12M | — | -$203M | -$204M | — |
| 2020 | $10M | — | -$72M | -$72M | — |
| 2019 | $21M | — | -$26M | -$26M | — |
| 2018 | $16M | — | -$22M | -$22M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $271M | $57M | $214M | $231M | — |
| 2024 | $344M | $103M | $241M | $237M | — |
| 2023 | $429M | $151M | $279M | $292M | — |
| 2022 | $450M | $180M | $270M | $392M | — |
| 2021 | $393M | $165M | $228M | $370M | $15M |
| 2020 | $476M | $80M | $397M | $463M | $15M |
| 2019 | $82M | $56M | $26M | $71M | $15M |
| 2018 | $44M | $31M | $14M | $37M | $10M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$74M | $230,000 | -$75M |
| 2024 | -$60M | $648,000 | -$60M |
| 2023 | -$18M | $3M | -$21M |
| 2022 | $32M | $8M | $24M |
| 2021 | -$135M | $3M | -$138M |
| 2020 | -$43M | $2M | -$45M |
| 2019 | -$6M | $818,000 | -$7M |
| 2018 | -$21M | $1M | -$22M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ARCT)